Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhibition of Oral Tumorigenesis by Antitumor B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04278989
Recruitment Status : Not yet recruiting
First Posted : February 20, 2020
Last Update Posted : July 20, 2021
Sponsor:
Information provided by (Responsible Party):
Stuart Wong, Medical College of Wisconsin

Brief Summary:
This is a randomized, double-blinded, placebo-control window of opportunity study of Anti-tumor B versus placebo. Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.

Condition or disease Intervention/treatment Phase
Squamous Cell Cancer of the Oral Cavity Drug: Anti-tumor B Drug: Placebos Early Phase 1

Detailed Description:

One of the most promising chemopreventive agents to prevent head and neck cancer is Antitumor B (ATB), a Chinese herbal mixture.

This randomized Window of Opportunity trial will enroll patients with resectable stage I-IVB squamous cell cancer of the oral cavity who are candidates for surgical tumor resection. Participants will agree to allow a portion of the standard of care (diagnostic tumor biopsy) to be used for the study, and to take study agents or placebo for a duration (14 to 21 days) until the time of their surgery. A second, post-treatment tumor biopsy is not needed because the OR-resected tumor will serve this purpose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Inhibition of Oral Tumorigenesis by Antitumor B
Estimated Study Start Date : September 1, 2021
Estimated Primary Completion Date : December 1, 2023
Estimated Study Completion Date : December 1, 2024

Arm Intervention/treatment
Active Comparator: Anti-tumor B
1,200 mg three times a day.
Drug: Anti-tumor B
1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).
Other Names:
  • Zeng-Sheng-Ping
  • ACAPHA
  • ATB

Placebo Comparator: Placebo
Placebo taken three times a day.
Drug: Placebos
Placebos taken seven to 28 days (dependent on scheduled surgery).




Primary Outcome Measures :
  1. Tumor Ki-67 in baseline tumor biopsy compared to resected tumor. [ Time Frame: Baseline and following surgery (seven to 28 days after baseline) ]
    KI-67 will be measured as a change in the index from baseline to post-treatment (surgery).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  2. Clinical diagnosis of oral cavity squamous cell cancer.
  3. Patient can start study agent administration but histological confirmation of squamous cell cancer (SCC) of the oral cavity (or histologic variants of SCC) by the pathologist must happen within seven days of registration in order to continue protocol therapy.
  4. Clinical stage II-IVA (as defined by the American Joint Committee on Cancer (AJCC), 8th Edition), and amenable to surgical resection.
  5. New diagnosis of oral SCC, new second primary, or recurrent oral SCC following a minimum remission of six months following previous definite surgery.
  6. History and physical examination by an otolaryngologist and medical oncologist within 14 calendar days of study registration.
  7. Zubrod/ECOG Performance status < 2.
  8. Age ≥ 18 years.
  9. Complete Blood Count (CBC)/differential obtained within 14 calendar days prior to registration, with adequate bone marrow function defined as follows:

    • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3;
    • Platelets ≥ 100,000 cells/mm3;
    • Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable).
  10. Adequate renal and hepatic function within 14 calendar days prior to registration, defined as follows:

    • Serum creatinine < 1.5 mg/dl or creatinine clearance (CCr) ≥ 50 ml/min within 14 calendar days prior to registration, determined by 24-hour collection or estimated by Cockcroft-Gault formula:
    • CCr male = [(140 - age) x (wt in kg)]
    • [(Serum Cr mg/dl) x (72)]
    • CCr female = 0.85 x (CrCl male)
  11. Total bilirubin < 2 x the institutional upper limit of normal (ULN);
  12. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x the institutional ULN;
  13. Magnesium, calcium, glucose, potassium, and sodium within 14 calendar days prior to registration, with the following required parameters:

    • Magnesium: > 0.9 mg/dl or < 3 mg/dl;
    • Calcium: > 7 mg/dl or < 12.5 mg/dl;
    • Glucose: > 40 mg/dl or < 250 mg/dl;
    • Potassium: > 3 mmol/L or < 6 mmol/L;
    • Sodium: > 130 mmol/L or < 155 mmol/L.
  14. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  15. Female subjects must meet one of the following:

    • Postmenopausal for at least one year before enrollment, OR
    • Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR
    • If subject is of childbearing potential (defined as not satisfying either of the above two criteria), agrees to practice two acceptable methods of contraception (combination methods require use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 21days after the last dose of study agent, OR
    • Agrees to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)
  16. Male subjects, even if surgically sterilized (i.e., status postvasectomy), must agree to one of the following:

    • Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR
    • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)
  17. Enrollment on an interventional postoperative study is allowed if study agents do not overlap.
  18. Gastric tube drug administration is permissible.

Exclusion Criteria:

  1. Pregnant or lactating women are ineligible due to unforeseeable risks to embryo or fetus.
  2. Concurrent use of any medicinal botanical, natural, or other herbal compounds.
  3. Planned subtotal or debulking surgery is not permissible.
  4. Prior systemic chemotherapy for oral SCC; note that prior chemotherapy for a different cancer is allowable.
  5. Prior radiotherapy for oral SCC is permissible if disease free for one year since prior oral cancer treatment and free of significant late radiation effects.
  6. Severe active comorbidity, such as uncontrolled cardiac disease, infection, and severe chronic obstructive pulmonary disease (COPD).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04278989


Contacts
Layout table for location contacts
Contact: Medical College of Wisconsin Cancer Center Clinical Trials Office 414-805-8900 cccto@mcw.edu

Locations
Layout table for location information
United States, Wisconsin
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Contact: Medical College of Wisconsin Cancer Center Trials Office    414-805-8900    cccto@mcw.edu   
Principal Investigator: Stuart J. Wong, MD         
Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Layout table for investigator information
Principal Investigator: Stuart J Wong, MD Medical College of Wisconsin
Layout table for additonal information
Responsible Party: Stuart Wong, Professor, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT04278989    
Other Study ID Numbers: PRO00037907
First Posted: February 20, 2020    Key Record Dates
Last Update Posted: July 20, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Squamous Cell
Carcinoma, Squamous Cell
Carcinogenesis
Cell Transformation, Neoplastic
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma
Neoplastic Processes
Pathologic Processes